BACKGROUND Bioprosthetic valve thrombosis (BPVT) is considered uncommon; this may be related to the fact that it is often unrecognized. Recent data suggest that BPVT responds to vitamin K antagonists, emphasizing the need for reliable diagnosis.
The Mayo Clinic Institutional Review Board approved the study protocol. The pathology and surgical databases were used to identify all BPVs explanted from adults (age $18 years). We reviewed the pathology reports of 397 patients whose prostheses were explanted within the study period, and BPVT was considered to be present whenever valve thrombosis was the main mechanism of BPV dysfunction (n ¼ 46). We then matched BPVs that were explanted for structural valve failure to cases of BPVT (1 BPVT: 2 structural valve failures). The structural valve failure group was matched by age (AE5 years), sex, and prosthesis position. To estimate the overall incidence of BPVT in our surgical practice, we also recorded the total numbers of BPV implantations performed at the were compared by the method of DeLong et al. (12) to determine the best combination of these clinical and echocardiographic predictors that identified BPVT, providing optimal balance between sensitivity and specificity.
RESULTS
Baseline clinical characteristics of BPVT and structural valve failure groups are shown in Table 1 . were patients with mixed disease (thrombosis and degeneration) in whom the main mechanism could not be established (n ¼ 4), those with active endocarditis (n ¼ 2), and those with history of thrombophilia (n ¼ 1). A diagnosis of BPVT was identified in the pathology report of 46 patients, of which 29 (63%) were aortic, 9 (20%) mitral, 7 (15%) tricuspid, and 1 (2%) pulmonary. Porcine valves were the most common type in the BPVT group (n ¼ 36; 78%), followed by pericardial valves (n ¼ 8; 18%) and homografts (n ¼ 2; 4%). Isolated stenosis without evidence of BPV regurgitation was seen in 25 (54%) patients; isolated prosthetic regurgitation was noted in only 5 (11%); and a mixed mechanism of prosthetic dysfunction was present in 15 (33%) patients.
A total of 92 patients with pathology-demonstrated structural failure and no thrombus were selected as matched controls. Porcine valves were explanted from 50 (54%), pericardial valves from 41 (45%), and homografts from 1 (1%). Isolated stenosis or regurgitation was seen each in 30 (33%) patients, while a mixed mechanism was noted in 32 (35%) patients.
BPVT patients and structural valve failure patients were well matched for main demographic characteristics ( Table 1) .
The overall prevalence of BPVT was 11.6% (46 of 397 explanted BPVs), with no significant differences among various valve positions ( Table 2 ). There were BPVT and structural valve failures is shown in Table 3 . ficity of 90% when we applied it to the 138 patients included in our cohort ( Table 5 ).
DISCUSSION
To the best of our knowledge, this is the first study PROSTHETIC DYSFUNCTION DUE TO BPVT. The predominant mechanism of BPV dysfunction is structural deterioration (1, 2) , and in the past, the risk of thrombosis was considered to be very low. In contrast, our experience and that of others suggest that BPVT is not uncommon (6, 7, 13, 14) . Butnaru et al. . Interestingly, persistent AF was not an independent risk factor for BPVT.
Our data suggest that inadequate anticoagulation is significant in both persistent and paroxysmal AF.
Most patients with paroxysmal AF in our cohort were not anticoagulated and that might be the reason for their increased risk of BPVT, as shown in our multivariate analysis. Egbe et al. In a previous report we identified another 15 BPVT patients treated with anticoagulation alone in a Tables 1 and 3 . Egbe et al. 
